Recursion Pharmaceuticals Inc. stocks have been trading up by 7.04 percent following upbeat coverage of its AI-driven drug discovery advancements.
Key Takeaways Traders Are Watching
- A $200M follow-on at $3.25 per share extended RXRX’s cash runway into 2029, with strong healthcare fund participation despite dilution.
- Early TUPELO data for REC-4881 in FAP showed meaningful GI polyp reductions, durable benefit after stopping therapy, and a safety profile in line with MEK1/2 inhibition.
- Molecular glue REC-1245 delivered three partial responses and a 91.7% disease control rate in heavily pretreated solid tumors, with a clear plan for dose expansion.
- Sanofi exercised its first option in the AI-driven collaboration with Recursion, adding an oral immunology candidate to its pipeline and triggering a $10M milestone, plus over $300M in potential future milestones.
- ARK, led by Cathie Wood, snapped up 4.2M RXRX shares as the stock spiked 15.4% to $4.32, while Morgan Stanley inched its price target up to $5.90 with an Equal Weight rating.
Live Update At 12:32:31 EDT: On Wednesday, October 28, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 7.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RXRX has been climbing out of a deep biotech hole. Over the last few weeks, Recursion Pharmaceuticals shares have pushed from the low $3s to around $4.33, with recent daily closes stepping higher from $3.58 to $4.33. That steady grind up shows dip buying and short covering are active in this name.
Intraday on the latest session, RXRX traded in a tight band between roughly $4.29 and $4.43 after gapping up from $4.00 at the open. That kind of controlled consolidation near the top of the day tells traders the market is digesting news rather than immediately dumping it. Volume-focused traders will see this as classic “flag” behavior after a sharp move.
More Breaking News
- ONDS Stock Draws Traders As Defense Backlog Explodes
- Genmab (GMAB) Stock Rockets As Rina-S Trial Success Energizes Bulls
- Artisan Partners Climbs 3% After Earnings Beat and Dividend Raise
- Bicara Therapeutics Falls 40%
Under the hood, Recursion is still a classic early-stage biotech story. Revenue is only about $74.3M, yet RXRX sports a rich price-to-sales ratio near 43, driven by hype around its AI drug discovery model. Profitability metrics are deeply negative, with EBITDA around -$112.5M and free cash flow about -$107.9M in the latest reported quarter. The bright spot: a strong balance sheet, including roughly $545.7M in cash and a current ratio near 5, now supported by the fresh $200M raise. For traders, that means plenty of runway to keep the story alive, but also a reminder this is a high-risk, story-driven chart, not a value play.
Why Traders Are Locked In On RXRX Right Now
RXRX is suddenly back on momentum screens because the story finally lined up: data, deals, and dollars all hit in the same window. Recursion Pharmaceuticals rolled out encouraging Phase 1b/2 TUPELO results for REC-4881 in familial adenomatous polyposis, showing substantial reductions in GI polyp burden and even sustained benefit after stopping treatment. For traders, that’s pipeline de-risking in a niche indication where any solid efficacy signal can matter.
At the same time, Recursion posted early Phase 1 data for its molecular glue REC-1245 targeting RBM39. Three partial responses and a 91.7% disease control rate in heavily pretreated solid tumors is not noise. It tells traders RXRX’s AI-driven discovery engine is spitting out clinically active drugs, not just slide-deck dreams. The focus on endometrial cancer in the dose-expansion plan gives a concrete path forward.
The big headline, though, is Sanofi. The pharma giant exercised its option on the first dual-target immunology candidate from the AI collaboration with Recursion, triggering a $10M milestone and bringing total payments to $144M so far. RXRX is now lined up for over $300M in additional milestones plus low double-digit royalties if programs advance, with Phase 1 planned for 2027. That’s real external validation of the platform.
Layer on top of that a $200M oversubscribed follow-on offering at $3.25, backed by high-quality healthcare funds, and the picture shifts. Yes, dilution stings, but RXRX now guides its cash runway out to 2029. That reduces financing overhang, which many biotech traders hate. Meanwhile, ARK’s 4.2M-share buy and a 15.4% pop to $4.32 brought in momentum players, even as Morgan Stanley’s modest price target bump to $5.90 keeps expectations in check.
Conclusion
RXRX now sits at the crossroads of AI hype and hard clinical data, and that mix is exactly what active traders look for. Recursion Pharmaceuticals has shored up its balance sheet with a $200M equity raise, extending cash into 2029 and giving itself time to run the TUPELO and REC-1245 programs deeper. The company is still burning heavy cash and running steep losses, but that’s standard for this stage of biotech.
What stands out is the layered catalyst stack. Near term, traders will watch the planned Q3 2026 results and the CGA-IGC webinar, where Recursion plans to showcase updated REC-4881 and REC-1245 data, plus key opinion leader and patient panels. A potential regulatory update on REC-4881 by year-end adds another spark for volatility in RXRX.
On the strategic side, Sanofi’s option exercise and the more than $300M milestone potential plus future royalties give RXRX a non-dilutive value stream if things keep progressing. ARK’s aggressive buying shows how quickly big thematic capital can swing into a name like Recursion once momentum turns, even while firms like Morgan Stanley stay measured with an Equal Weight rating.
For active traders, the playbook is clear: respect the uptrend, track the catalyst dates, and stay focused on risk control. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” In the same spirit, remember what Tim Sykes always says — “Cut losses quickly, because holding and hoping is not a strategy.” RXRX is shaping up as a high-potential, high-risk trading vehicle where discipline matters as much as any headline. This is strictly for educational and research purposes, but it’s a name that deserves a spot on the watchlist.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.